Fact CheckerSign in

NCT07184788Not yet recruitingPhase 2

G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

Glofitamab，Polatuzumab Vedotin and GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

Source: ClinicalTrials.gov · Last updated 22 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
80 (estimated)
First submitted
14 Sept 2025
Start date
1 Oct 2025
Primary completion date
1 Oct 2030
Lead sponsor
Navy General Hospital, Beijing
NCT number
NCT07184788

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 80
  • From 1 Oct 2025 to the primary completion date, 1 Oct 2030
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.

Other illness

  • Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.

Other

  • Pregnant or lactating women

Who the study is looking for

  • Pathologically confirmed Aggressive B-Cell Lymphoma (Including but not limited to diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, etc. according World Health Organization (WHO) classification;
  • Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
  • Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
  • Patient has not received chemotherapy previously.
  • Anticipated life expectancy at least 3 months

Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.